Related Experiment Videos
[Normal immune function in centroblastic-centrocytic and centroblastic lymphoma]
V Weisbach1, T Zeiler, J Zingsem
1Abteilung Innere Medizin, Universitätsklinikum Rudolf Vierchow-Standort Charlottenburg, Freie Universität Berlin.
Insights
Patients with centroblastic-centrocytic lymphoma and centroblastoma exhibit low, yet normal, in vitro immune function. Their lymphocyte reactivity mirrors that of healthy individuals with the lowest immune response.
Area of Science:
- Immunology
- Oncology
- Hematology
Context:
- Investigating immune system function in patients with non-Hodgkin lymphomas.
- Evaluating lymphocyte reactivity, cell counts, and granulocyte function.
- Utilizing cluster analysis to define distinct immune response profiles in healthy controls.
Purpose:
- To compare the in vitro immune function of patients with centroblastic-centrocytic lymphoma (CB-CC) and centroblastoma (CB) against healthy controls.
- To assess lymphocyte reactivity, lymphocyte subpopulations, and granulocyte functions in lymphoma patients.
Summary:
- In vitro lymphocyte reactivity, lymphocyte counts, and granulocyte functions were measured in 88 healthy controls and patients with CB-CC (n=10) and CB (n=7).
- Healthy controls were categorized into high, medium, and low responders based on lymphocyte reactivity.
- Both CB-CC and CB patients demonstrated lymphocyte reactivity comparable to the low-responding control group, indicating a low but normal in vitro immune function.
Impact:
- Reveals that specific malignant lymphomas present with immune function equivalent to low-responding healthy individuals.
- Provides insights into the immunodeficiency associated with CB-CC and CB lymphomas.
- Highlights the importance of comparing patient immune profiles to distinct control group clusters for accurate assessment.
Abstract:
We tested in vitro lymphocyte reactivity using 5 mitogens and 9 antigens, measured lymphocyte and lymphocyte subpopulation counts, granulocyte chemotaxis and adherence in 10 patients with centroblastic-centrocytic lymphoma (CB-CC), 7 patients with centroblastoma (CB) and 88 healthy controls. The control group could be divided into 3 clusters with significantly different lymphocyte reactivity by means of cluster and discrimination analysis (BMDP2N): 21 high-, 18 medium- and 49 low responders. Comparing lymphocyte reactivity of CB-CC and CB patients to each of the 3 immunofunctional different control groups yielded the surprising result that both malignant lymphomas are equivalent to the low responding control group and show a low, but still normal in vitro immune function.